LIVE UPDATES
Emzor Pharmaceuticals has announced its intention to build an Active Pharmaceutical Ingredients (API) facility in Sagamu, Ogun State, with an investment of $23 million (approximately N25 billion) to address the widespread threat of malaria in Nigeria and sub-Saharan Africa.
This decision was confirmed in a joint statement by Kunle Faloye, Head of Marketing and Strategy, and Uzoma Ezeoke, Executive Director at Emzor Pharmaceuticals.
The establishment of the API plant represents a significant step towards enabling local production of essential pharmaceutical ingredients necessary for producing anti-malarial drugs.
This initiative strengthens the anti-malarial supply chain and expands pharmaceutical manufacturing capacity on the continent.
In alignment with Sustainable Development Goal 3, which aims to ensure healthy lives for all, Emzor's efforts promise to protect millions of people in Africa from disease and disability.
The Project emphasizes financial inclusion and the health of pregnant women by manufacturing APIs intended to produce anti-malarial pharmaceuticals, including those for the Intermittent Preventive Treatment of malaria during pregnancy.
Upon completion, the API facility will be the first anti-malarial API manufacturing plant in Nigeria and Africa. It is projected to produce 400 metric tonnes of quality APIs annually, significantly accelerating the fight against malaria on the continent.
It is worth noting that during the EU-Nigeria Strategic Dialogue last October, the European Investment Bank (EIB) announced a 14 million Euros funding to Emzor Pharmaceutical Industries Limited to expedite the fight against malaria in Africa through the construction of the first anti-malaria API manufacturing plant in Nigeria.
This project aims to reduce Nigeria’s dependence on importing over 90 percent of its API and will focus on producing high-quality and affordable anti-malarial drugs, marking a significant advancement in Africa’s healthcare sector.
